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With an incidence of ~1 in 800 births, Down syndrome (DS) is the most common chromosomal condition linked to intellectual disability worldwide. While
the genetic basis of DS has been identiﬁed as a triplication of chromosome
21 (HSA21), the genes encoded from HSA21 that directly contribute to cognitive deﬁcits remain incompletely understood. Here, we found that the HSA21encoded chromatin effector, BRWD1, was upregulated in neurons derived
from iPS cells from an individual with Down syndrome and brain of trisomic
mice. We showed that selective copy number restoration of Brwd1 in trisomic
animals rescued deﬁcits in hippocampal LTP, cognition and gene expression.
We demonstrated that Brwd1 tightly binds the BAF chromatin remodeling
complex, and that increased Brwd1 expression promotes BAF genomic mistargeting. Importantly, Brwd1 renormalization rescued aberrant BAF localization, along with associated changes in chromatin accessibility and gene
expression. These ﬁndings establish BRWD1 as a key epigenomic mediator of
normal neurodevelopment and an important contributor to DS-related
phenotypes.

Down syndrome (DS) is the most common form of autosomal aneuploidy in humans, and is characterized by physical growth
delays, skeletal abnormalities, neurological deﬁcits and cognitive
impairments1. Although the genetic cause of DS is full or partial triplication of chromosome 21 (HSA21)2,3, triplicated genes on HSA21 do
not fully account for the widespread transcriptional dysregulation
observed in DS. Recent RNA-sequencing of human postmortem
DS brain tissues demonstrated robust gene expression changes across
all chromosomes (both up- and downregulated) throughout
development4, with ~70% of triplicated HSA21 genes being subject to
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dosage compensation, which buffers against increased expression5.
Numerous studies in both human-derived cells, brain tissues4,6, and
rodent models of DS1,7,8 have found that there is not a clear 1:1 relationship between gene dosage and gene expression at trisomic loci,
further suggesting that DS phenotypes may be driven by more complex regulatory mechanisms. In addition, given the tremendous
amount of variability in the severity and clinical presentation of DS5,
it is believed that epigenetic processes may also contribute to global
patterns of transcriptional dysregulation, both during neurodevelopment and in adulthood. However, our understanding of how
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chromatin-based mechanisms contribute to DS phenotypes remains
limited. HSA21 encodes several chromatin regulators9, including
BRWD110, a WD-repeat and bromodomain-containing protein10. In
previous studies focusing on germ11 and immune cells12,13, BRWD1 was
shown to modulate chromatin structure via proposed interactions
with the mammalian SWI/SNF (BAF) ATP-dependent chromatinremodeling complex14,15. However, despite being encoded on HSA21,
and its demonstrated activity as an epigenetic regulator, potential
roles for BRWD1 in the context of HSA21 triplication and DS pathophysiology have not yet been explored.
Here, we found that BRWD1 is upregulated in both trisomic
human neurons and Ts65Dn mouse brain. Selective restoration of
Brwd1 copy number in trisomic mice rescued DS-related cognitive
impairments, neuronal physiology, and alterations in transcription. In
adult euploid mice, acute Brwd1 overexpression in dorsal hippocampus was sufﬁcient to impair memory, attenuate activity-induced
gene expression and promote excitation/inhibition imbalance. Furthermore, we found that Brwd1 tightly associates with the BAF complex in both embryonic and adult brain, and that restoring Brwd1 copy
number in trisomic animals substantially rescued alterations in BAF
genomic localization, as well as associated changes in neuronal chromatin accessibility. These data demonstrate a dosage-sensitive role for
Brwd1 in targeting BAF complexes to appropriate loci within the central nervous system, and indicate a central role for BRWD1 in the precipitation of neurological deﬁcits associated with DS.

Results
BRWD1 is upregulated in neurons derived from iPS cells from an
individual with DS and DS-like rodent brain
Given that not all HSA21 genes are dysregulated at the level of transcription in DS, we ﬁrst generated human induced pluripotent stem
(iPS) cell-derived forebrain neurons from a DS subject to assess whether BRWD1 levels are indeed increased as a result of HSA21 triplication. In doing so, we found that BRWD1 expression was elevated in
neurons derived from iPS cells from an individual with DS vs. a
respective isogenic control (Supplementary Fig. 1a, b). Next, in order to
explore potential mechanistic roles for BRWD1 in mediating trisomy
21-related phenotypes, we measured Brwd1 expression in brain tissues
of Ts65Dn mice, a well characterized model of DS with segmental
trisomy 16 and a corresponding copy number triplication for
approximately half of the homologous HSA21 genes, including
BRWD116–18. Consistent with previous studies in humans with DS and
trisomic mice1,4,18,19, we found that Brwd1 mRNA was signiﬁcantly elevated in both embryonic (E17.5) and adult (6-week) male and female
Ts65Dn brain tissues, including the prefrontal cortex (PFC), hippocampus and cerebellum—with no signiﬁcant difference between the
sexes in adult euploid animals (Fig. 1a and Supplementary Fig. 2a, b).
To further conﬁrm the etiological relevance of this trisomic mouse
model to human DS at the level of transcription, we next performed
RNA-seq proﬁling on E17.5 Ts65Dn vs. euploid forebrain tissues. Differential expression analyses demonstrated that the Ts65Dn mouse model
exhibits robust transcriptional changes that overlap signiﬁcantly with
human DS single-nuclei gene expression proﬁles in postmortem PFC
(Supplementary Fig. 3a, b)20. Of note, we found that only upregulated
genes in Ts65Dn vs. euploid mice overlapped signiﬁcantly with human
DS-associated gene expression, which included genes enriched for
pathways associated with cellular development, neuronal differentiation, and synaptic transmission. These data suggest that inappropriate
induction of transcripts related to neuronal function may contribute to
DS-related phenotypes in Ts65Dn mice (Supplementary Fig. 3c).

BRWD1 copy number restoration rescues physiological and
cognitive hippocampal deﬁcits in adult male Ts65Dn mice
Given that Brwd1 expression was found to be upregulated in Ts65Dn
mouse brain, we next examined whether Brwd1 itself may contribute
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to DS-related phenotypes by genetically restoring Brwd1 copy number
in otherwise trisomic mice. We crossed Ts65Dn females to heterozygote Brwd1+/– 11 males, resulting in male and female offspring of four
genotypes: euploid, Brwd1+/–, Ts65Dn, and Ts65Dn;Brwd1+/– (Fig. 1b).
Importantly, the Ts65Dn;Brwd1+/– cross selectively rescued Brwd1 triplication observed in male Ts65Dn mice without directly genetically
restoring the trisomic background (Fig. 1c). However, in female mice,
while Brwd1 expression was signiﬁcantly reduced in Ts65Dn; Brwd1+/–
vs. Ts65Dn animals, we identiﬁed only trending Brwd1 increases in
Ts65Dn vs. euploid mice when comparing all four genotypes (Supplementary Fig. 2c), reﬂecting higher variability in Brwd1 upregulation
in female Ts65Dn hippocampus. Indeed, female Ts65Dn mice displayed more modest hippocampal Brwd1 fold-change (FC) differences
vs. euploid (average 1.19 FC) in comparison to those detected in males
(average 1.41 FC). These ﬁndings are consistent with previous studies in
which BRWD1 has been shown to display sex-speciﬁc functions and
expression levels, particularly in the context of early reproductive
cellular genesis11,21.
Next, to examine the impact of Brwd1 copy number restoration on hippocampal synaptic function in adult mice (6-week), we
performed ex-vivo brain slice long-term potentiation (LTP)
recordings, where LTP was induced by theta-burst stimulation at
Schaffer collateral inputs to area CA1. Consistent with previous
studies22,23, LTP was signiﬁcantly impaired in slices from Ts65Dn
male mice vs. euploid controls - however, this deﬁcit was fully
rescued in Ts65Dn;Brwd1+/– animals, while Brwd1 heterozygosity
did not affect LTP (Fig. 1d). These deﬁcits were speciﬁc to more
stable forms of neuronal plasticity, as other measures of baseline
synaptic function were unaffected in Ts65Dn animals (Supplementary Fig. 4a, b). Interestingly, in females, LTP was not affected
in Ts65Dn mice vs. euploid controls, and no differences in LTP
were observed comparing euploid females vs. Ts65Dn; Brwd1+/– or
Brwd1+/– genotypes (Supplementary Fig. 2d). These ﬁndings parallel previous reports that have identiﬁed regional differences in
brain function between male and female Ts65Dn mice, as well as
in other mouse models of DS24,25, suggesting that males may
exhibit more severe hippocampal deﬁcits vs. females.
Next, to investigate whether hippocampal-dependent cognitive
deﬁcits associated with DS might be improved in Ts65Dn;Brwd+/animals, we employed a rodent contextual fear conditioning (FC)
paradigm to assess learning and memory in the four genotypes
described above. Male Ts65Dn mice displayed a signiﬁcant reduction
in FC memory vs. euploid controls—a deﬁcit that was fully rescued with
Brwd1 renormalization, with no effect of Brwd1 heterozygosity
observed (Fig. 1e). Although we did not detect altered hippocampal
LTP in female Ts65Dn mice, we did ﬁnd that female Ts65Dn mice
scored worse in the contextual FC memory task vs. euploid controls
(Supplementary Fig. 2e), suggesting that distinct molecular mechanisms may contribute to contextual fear learning in male vs. female
Ts65Dn mice. Furthermore, Brwd1 copy number restoration did not
signiﬁcantly rescue these cognitive deﬁcits, reﬂecting a more limited
contribution of Brwd1 to Ts65Dn hippocampal function in females.
Together, these data indicate that in male animals, increased Brwd1
gene dosage is necessary for the precipitation of DS-related physiological and cognitive hippocampal deﬁcits in the Ts65Dn
mouse model.

BRWD1 overexpression in adult male hippocampus is sufﬁcient
to induce cognitive and physiological defects in euploid animals
We then investigated whether acute Brwd1 overexpression in euploid
animals may be sufﬁcient to cause DS-related cognitive deﬁcits. We
generated herpes simplex virus (HSV) vectors to overexpress BRWD1
(HSV-BRWD1-GFP) vs. an empty vector control (HSV-GFP) in adult male
dorsal hippocampus (CA1), followed by a battery of behavioral assays
to assess the impact of Brwd1 overexpression on context- and spatial2
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Fig. 1 | Brwd1 copy number restoration rescues synaptic and cognitive deﬁcits
in male trisomic animals. a qPCR expression data for Brwd1 in embryonic day (E)
17.5 forebrain (FB) and adult (6-week) PFC, hippocampus (HIPP) and cerebellum
(CER) from euploid vs. Ts65Dn male mice. A.U. = Arbitrary Units, with experimental
(non-euploid) group averages normalized to respective euploid controls.
b Schematic depicting the generation of mouse genotypes to be investigated.
c qPCR expression data for Brwd1 in euploid vs. Brwd1+/– vs. Ts65Dn vs.
Ts65Dn;Brwd1+/– E17.5 forebrain. d Deﬁciency of hippocampal LTP in adult male (6-

week) Ts65Dn mice is rescued by Brwd1 copy number restoration. The representative traces were recorded at the end of the baseline period (dashed lines) and
60 min after induction of LTP (solid lines). Calibrations: 0.5 mV/5 ms. e Context
dependent fear conditioning—displayed as % freezing in the trained context—
comparing euploid vs. Brwd1+/– vs. Ts65Dn vs. Ts65Dn;Brwd1+/– mice. Data are
presented as averages ± SEM. See Supplementary Information Materials for full
caption with n’s and statistics. Source data are provided as a source data ﬁle.

dependent learning and memory, as well as anxiety and anhedonia
related behaviors. We found that selectively upregulating Brwd1
expression to levels similar to those observed in Ts65Dn animals was
sufﬁcient to elicit signiﬁcant cognitive deﬁcits in hippocampaldependent tasks (Supplementary Fig. 5a–o). Next, to explore the
electrophysiological impact of overexpressing Brwd1 in adult euploid
male hippocampus, we performed patch clamp recordings of virally
infected (HSV-BRWD1-GFP vs. HSV-GFP) CA1 pyramidal neurons. Our
results indicated that Brwd1 overexpression signiﬁcantly increased
both neuronal excitability (Supplementary Fig. 6a) and the frequency
of spontaneous excitatory post-synaptic currents (sEPSC; Supplementary Fig. 6b), while signiﬁcantly reducing the frequency of inhibitory post-synaptic currents (sIPSC; Supplementary Fig. 6c). sEPSC and
sIPSC amplitudes were unaffected by Brwd1 overexpression (Supplementary Fig. 6b, c). Finally, we observed reduced immediate early gene

(IEG) induction in Brwd1 overexpressing CA1 following exposure to a
novel environment (Supplementary Fig. 6d), suggesting that BRWD1
overexpression leads to shifts in excitation/inhibition balance and
neuronal plasticity that may prevent stable induction of normal LTP.
Together with our previous results, these data demonstrate that Brwd1
upregulation in DS-like brain is both necessary and sufﬁcient to promote synaptic and cognitive deﬁcits associated with the disorder, and
that Brwd1 copy number restoration fully rescues these effects in
male mice.
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BRWD1 triplication contributes to gene expression abnormalities in DS-like brain
We next sought to explore Brwd1’s role in regulating neuronal gene
expression patterns in DS-like brain by performing RNA-seq analyses
on primary neuronal cultures derived from euploid vs. Ts65Dn vs.
3
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Fig. 2 | Rescue of aberrant gene expression in male trisomic brain by Brwd1
renormalization. a RNA-seq heatmaps of DE genes comparing euploid vs. Ts65Dn
vs. Ts65Dn;Brwd1+/– adult male (6-week) hippocampus. Normalized RNA expression
values (averaged between replicates) were used to generate z-scores for each row.
b Normalized heatmaps of RNA expression values for DE genes in adult male hippocampus that display pairwise signiﬁcant regulation between Ts65Dn vs. euploid,
and are rescued in Ts65Dn;Brwd1+/– vs. Ts65Dn. c Heatmap displays Jaccard index,

as well as adjusted p-values, from odds ratio analyses of the overlap between DE
genes from euploid vs. Ts65Dn vs. Ts65Dn;Brwd1+/– comparisons and previously
published human DS single-nuclei RNA-seq data vs. age-matched controls20. d Bar
graph of −log10(adj. p-val) for gene ontology (GO) processes displaying enrichment
for PCGs identiﬁed in c above. See Supplementary Information Materials for full
caption with n’s and statistics. Source data are provided as a source data ﬁle.

Ts65Dn;Brwd1+/ embryonic mouse forebrain (mixed male and female).
Using this embryonic neuronal system, which was maintained in the
absence of proliferating glial cells, we observed widespread changes in
gene expression, detecting 9588 differentially expressed (DE) protein
coding genes (PCGs) when comparing across all three genotypes in a
likelihood ratio test (Supplementary Fig. 7a). Separate pairwise comparisons between Ts65Dn vs. euploid and Ts65Dn;Brwd1+/– vs. Ts65Dn
groups revealed that the majority of differentially expressed PCGs in
Ts65Dn vs. euploid neurons were reversed (~60.3% rescue) by Brwd1
copy number restoration (Supplementary Fig. 7b), with rescued genes
signiﬁcantly enriched for gene ontology (GO) terms including axogenesis, synaptic transmission and regulation of neuronal morphology
(Supplementary Fig. 7c). These data demonstrate that Brwd1 plays a
critical role in maintaining normal patterns of neuronal gene expression during brain development.
In order to further evaluate the effects of Brwd1 rescue within the
context of adult brain, we performed RNA-seq on hippocampal tissues
from 6-week-old male animals, comparing Ts65Dn vs. euploid and
Ts65Dn;Brwd1+/– genotypes (Fig. 2a). Pairwise comparisons identiﬁed
963 DE genes (FDR < 0.1) between Ts65Dn vs. euploid, and 801 DE
genes (FDR < 0.1) between Ts65Dn;Brwd1+/– vs. Ts65Dn, with ~17% of DE
genes in Ts65Dn vs. euploid mice being signiﬁcantly reversed in their
expression with Brwd1 copy number restoration (Fig. 2b). Consistent
with our earlier analyses examining E17.5 forebrain tissues (Supplementary Fig. 3), odds-ratio assessments revealed signiﬁcant overlaps
with human DS associated gene expression, speciﬁcally for PCGs
upregulated in Ts65Dn vs. euploid, and for those downregulated in
Ts65Dn;Brwd1+/– vs. Ts65Dn animals, indicating that Brwd1 copy
number restoration signiﬁcantly reverses trisomic gene expression

patterns in Ts65Dn male hippocampus that are relevant to human DS
(Fig. 2c). Functional annotation analysis of rescued PCGs in adult male
hippocampus against GO databases demonstrated signiﬁcant enrichment of gene sets related to neuronal differentiation, neuronal morphology and synaptic function, consistent with observed deﬁcits in
synaptic function and hippocampal memory in male Ts65Dn
mice (Fig. 2d).
In female mice, a more modest rescue (~9.2%) of hippocampal
gene expression changes with Brwd1 normalization was observed
(Supplementary Fig. 8a, b). Associated processes/pathways for rescued genes in female mice were distinct from those seen in males, with
signiﬁcant GO term enrichment identiﬁed for protein synthesis and
translation, as well as neuronal differentiation (Supplementary Fig. 8c).
In addition, the genes that were found to be differentially expressed
between female vs. male Ts65Dn most signiﬁcantly associated with
LTP and neuronal morphology, highlighting potential molecular and/
or anatomical differences between the sexes in the pathophysiology of
DS-related deﬁcits (Supplementary Fig. 8d). Notably, in all cases (E17.5
forebrain, adult male and female hippocampus), differentially
expressed genes from Ts65Dn animals were not limited to trisomic
loci, consistent with previous ﬁndings4,26, and Brwd1 renormalization
reversed the expression of many of these genes across all chromosomes (Supplementary Fig. 9a).
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Brwd1 interacts with the BAF chromatin remodeling complex to
inﬂuence its genomic targeting in DS-like brain
To further explore the biochemical mechanisms through which
BRWD1 exerts its effects on synaptic plasticity, cognition and gene
expression in DS, we sought to examine whether BRWD1 might
4
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function independently or as a part of a protein complex. Given the
current lack of validated antibodies for BRWD1 in rodent brain tissues,
we generated and fully validated knock-in mice that endogenously
express BRWD1 with C-terminal FLAG-HA tags (Brwd1FLAG-HA) (Supplementary Fig. 10a–g). We precipitated soluble nuclear proteins from
E17.5 or adult, wildtype (untagged) vs. Brwd1FLAG-HA whole mouse brains
with ammonium sulfate (Fig. 3a) and detected speciﬁc HA signal at the
expected size of endogenous BRWD1-FLAG-HA protein by Western
blot (Supplementary Fig. 11a, b). Native soluble nuclear proteins were
then separated by density over a 10–30% glycerol gradient. The gradient fractions were immunoblotted for HA to indicate endogenous
BRWD1-FLAG-HA and for nuclear protein complexes of known size. A
single peak of full-length endogenous BRWD1-FLAG-HA was detected
in high-density fractions containing the canonical BAF (~2 MDa) and
PBAF (~3 MDa)27 complexes (Fig. 3b and Supplementary Fig. 11c).
Notably, BRWD1-FLAG-HA (261 kDa) was not detected in low-density
fractions containing AP-1 (160–440 kDa)28. These results suggested
that BRWD1 functions as part of a large protein complex.
Given BRWD1’s role as a chromatin interacting protein12–14, we next
tested the hypothesis that BRWD1 directly interacts with the BAF
complex by performing a series of BAF immunoprecipitation (IP)
experiments from embryonic or adult, wildtype vs. Brwd1FLAG-HA brain
nuclear extracts. At E17.5, the embryonic mouse brain is predominantly
composed of immature neurons and neural progenitors27. Upon
mitotic exit, neural progenitor BAF (npBAF) subunits SS18, ACTL6A
(BAF53a) and DPF2 (BAF45d) are downregulated, and neuronal subunits SS18L1 (CREST), ACTL6B (BAF53b) and DPF1/3 (BAF45b/c) are
upregulated, leading to the formation of the neuronal-speciﬁc BAF
(nBAF) complex27,29–31. To learn if BRWD1 associates with BAF complexes during neural development, we immunoprecipitated (IP’d) BAF
complexes from E17.5 brain nuclear extracts with antibodies to the
homologous subunits SS18 (npBAF) or SS18L1 (nBAF), to the core BAF
ATPase SMARCA4 (BRG1) or to IgG as a control. Endogenous BRWD1FLAG-HA robustly co-IP’d with antibodies to SMARCA4 and SS18
(npBAF), and to a lesser extent SS18L1 (nBAF), indicating that BRWD1
associates with both npBAF and nBAF complexes in embryonic brain
(Fig. 3c). We next immunoprecipitated BAF complexes from adult
wildtype vs. Brwd1FLAG-HA brain. We found that BRWD1-FLAG-HA co-IP’d
with antibodies to core BAF subunits SMARCA4, SMARCC2 and
SMARCB1; and with two different antibodies to the neuronal subunit
SS18L1 (Fig. 3d and Supplementary Fig. 11b). Next, the stability of the
BAF:BRWD1-FLAG-HA interaction was challenged with increasing
concentrations of the denaturing agent, urea. In previous studies,
transcription factor interactions with BAF were destabilized in as little
as 0.25 M urea, while core BAF subunits resisted denaturation in up to
4 M urea32,33. Although ~60% of BRWD1 was destabilized in 0.5 M urea,
we found that 40% remained bound to BAF through 4 M urea, surpassing the stability of the dedicated BAF subunit, SMARCB1 (Fig. 3e,
and quantiﬁed in Fig. 3f). Thus, BRWD1 stably associates with BAF
complexes in both embryonic and adult brain.
Since BRWD1 tightly interacted with BAF and co-migrated with it
on the gradient, we next explored the possibility that BRWD1 is a
dedicated subunit of BAF. Deleting BAF subunits can affect its
assembly and migration glycerol gradients34. Therefore, we subjected
nuclear extracts from Brwd1 knockout mice to density sedimentation
on a 10–30% glycerol gradient. Brwd1-/- BAF complexes migrated normally, indicating that BRWD1 was not necessary for BAF assembly and
did not contribute to the apparent molecular weight of BAF, possibly
owing to substoichiometry (Supplementary Fig. 11d). We then subjected brain nuclear extracts from E17.5 or adult Brwd1FLAG-HA mice to 3
rounds of immunodepletion with antibodies to BAF subunits or IgG, as
indicated in the co-IPs in Fig. 3c, d. Antibodies to SMARCA4, SS18 and
SS18L1 selectively and near-completely immunodepleted their target
proteins from E17.5 brain nuclear extracts; however, non-target BAF
subunits were co-depleted by only 20–30%, and BRWD1-FLAG-HA was
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depleted by ~20% only with the SS18 antibody (Supplementary Fig. 12a,
b). From adult brain nuclear extracts, antibodies to SMARCA4 and
SS18L1 immunodepleted their target proteins by 50–70%, while nontarget BAF subunits were depleted by 20–50%, and BRWD1 was
depleted by ~20% on average (Supplementary Fig. 12c–e). Although
BRWD1 was immunodepleted in a similar manner to BAF subunits, we
were unable to fully immunodeplete BAF complexes from nuclear
extracts and therefore could not determine if BRWD1 is indeed dedicated to BAF.
Given BRWD1’s chromatin binding domains (bromo- and WD40
repeats) and stable interaction with BAF, we next investigated whether Brwd1 upregulation in Ts65Dn mice may affect BAF genomic
targeting and whether Brwd1 copy number restoration might rescue
any deﬁcits observed. We performed ChIP-seq for the BAF complex
using an antibody that recognizes SMARCA2/4 in euploid vs. Ts65Dn
vs. Ts65Dn;Brwd1+/– hippocampus from adult (6-week) males. In
euploid animals, we detected the BAF complex primarily enriched at
gene promoters, gene bodies and enhancers (Fig. 4a and Supplementary Fig. 13a–c), loci also marked by active histone PTMs, such as
H3K27ac, H3K4me1, H3K4me3, H3K36me3, and H4K20me1) (Supplementary Fig. 13b). Importantly, differential analyses revealed that
in Ts65Dn vs. euploid hippocampus, ~60.5% (2156/3563) of all
SMARCA2/4 enriched protein coding gene (PCG) sites in euploid
animals are altered in trisomic brain, with ~27.6% (595/2,156) of those
differentially enriched sites being rescued by Brwd1 copy number
restoration (Fig. 4b and Supplementary Fig. 13c). More speciﬁcally, in
Ts65Dn, we found that SMARCA2/4 binding was lost at promoters
(64.1% downregulated events) compared to euploid (Supplementary
Fig. 13c), and robustly increased in intergenic regions (90.2% upregulated events) (Supplementary Fig. 13c). Mapping these sites of
differential SMARCA2/4 enrichment in mouse Ts65Dn brain against
chromatin states identiﬁed from human brain, we similarly found
that the BAF complex is mistargeted in trisomic hippocampus away
from promoters or “poised” promoters and towards repressed
genomic regions (e.g., repressed enhancers, heterochromatic loci
and repetitive regions of the genome) (Fig. 4c and Supplementary
Fig. 14a, b). Further odds ratio analyses revealed that PCGs that lost
SMARCA2/4 binding in Ts65Dn vs. euploid hippocampus overlapped
most signiﬁcantly with upregulated genes in both Ts65Dn and human
DS, as well as with rescued downregulated genes in Ts65Dn;Brwd1+/–,
suggesting that BAF complex mistargeting away from promoters is
associated with inappropriate induction of gene expression (Supplementary Fig. 13d, e). Finally, gene pathways signiﬁcantly associated with rescued SMARCA2/4-bound PCGs (595 genes from
Fig. 4b, c) included neuronal morphogenesis, synaptic transmission,
and LTP (Fig. 4d), which is consistent with our earlier ﬁndings from
bulk RNA-seq analyses presented in Fig. 2.
Based on BAF’s chromatin remodeling activity35, we predicted that
sites of differential SMARCA2/4 enrichment may also be associated
with changes in neuronal chromatin accessibility. To test this, we
performed neuronal-speciﬁc ATAC-seq in euploid vs. Ts65Dn vs.
Ts65Dn;Brwd1+/– hippocampus from adult (6-week) male mice to
identify differentially accessible chromatin regions across genotypes
(Fig. 4e, Supplementary Fig. 13c and f,g). Consistent with our previous
data, we found that Brwd1 copy number normalization signiﬁcantly
restored chromatin accessibility changes observed in Ts65Dn brain,
with ~65.1% (5,743/8,827) of differentially accessible PCG loci being
rescued in the Ts65Dn;Brwd1+/– genotype (Supplementary Fig. 13c). We
also detected a highly signiﬁcant overlap of PCGs that were found to be
up-and down-regulated in Ts65Dn vs. euploid and Ts65Dn;Brwd1+/– vs.
Ts65Dn, respectively (Fig. 4e). Finally, we employed odds ratio analyses to compare PCGs with differential SMARCA2/4 enrichment to
PCGs with altered chromatin accessibility in Ts65Dn animals. In doing
so, we identiﬁed a signiﬁcant association (~85%, 506/595) between
BRWD1-rescued PCGs in both SMARCA2/4 enrichment and chromatin
5
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Fig. 3 | BRWD1 tightly associates with the BAF complex in euploid brain.
a Schematic of mouse brain soluble nuclear protein extract (NE) preparation,
density sedimentation of nuclear proteins over a 10–30% glycerol gradient, and
immunoprecipitation of BAF chromatin remodeling complexes. Blue lettering
indicates neuronal-speciﬁc BAF subunits. Red lettering indicates PBAF-speciﬁc
subunits. b Density sedimentation of adult Brwd1FLAG-HA brain NE over a 10–30%
glycerol gradient indicates that BRWD1 predominantly associates with large protein
complexes. Subunits of BAF and AP-1 complexes serve as molecular weight markers: SMARCA2/4 antibody indicates all BAF complexes including non-canonical
GBAF (~1 MDa)75, canonical BAF (~2 MDa) and Polybromo-containing BAF (PBAF,
~3 MDa); ACTL6B and SS18L1 indicate neuronal-speciﬁc BAF complexes; c-Jun
indicates AP-1 (160–440 kDa). HA signal at the expected molecular weight of
BRWD1-FLAG-HA (~260 kDa) is observed in fractions containing the BAF complex.
c Endogenous BRWD1-FLAG-HA interacts with BAF complexes in embryonic brain.
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BAF complexes were immunoprecipitated from Brwd1FLAG-HA brain NE with antibodies against the BAF core ATPase SMARCA4, the neural progenitor subunit SS18,
the neuronal subunit SS18L1 or IgG as a control. Endogenous BRWD1-FLAG-HA
robustly co-immunoprecipitated with SMARCA4 and the neural progenitor subunit
SS18, but less so with the neuronal subunit SS18L1 from E17.5 brain. d BAF complexes puriﬁed from adult Brwd1FLAG-HA brain NE with antibodies against SMARCA4
or the neuronal subunit SS18L1 co-immunoprecipitate BRWD1-FLAG-HA. e The
stability of the BAF:BRWD1-FLAG-HA interaction was challenged with increasing
concentrations (0.25-4 M) of the denaturing agent, urea. A fraction of BRWD1
remained bound to BAF in up to 4 M urea, surpassing the stability of the dedicated
BAF subunit, SMARCB1. f Quantiﬁcation of urea denaturation experiments, as
shown in e, with the amount of bound protein normalized to the amount of
immunoprecipitated SMARCA4 (n = 3 experiments). Source data are provided as a
source data ﬁle. See Supplementary Fig. 15 for uncropped blots with MW markers.

6

Article

https://doi.org/10.1038/s41467-022-34200-0

Fig. 4 | Brwd1 renormalization partially rescues genomic BAF complex mistargeting in male trisomic brain. a Heatmaps of normalized SMARCA2/4
enrichment in euploid vs. Ts65Dn vs. Ts65Dn;Brwd1+/– adult male (6-week) hippocampus centered (±5 kb) over sites of differential SMARCA2/4 enrichment comparing Ts65Dn vs. euploid mice, separated by genomic context. b Volcano plot
depicting regulation of SMARCA2/4 enriched PCGs in euploid animals displaying
differential enrichment in Ts65Dn mice; gray circles = unregulated PCGs. Of the
PCGs regulated with respect to Smarca2/4 enrichment, 595 are rescued (red circles)
in Ts65Dn;Brwd1+/– mice, whereas the remainder of PCGs do not display such rescue
(black circles). c Relative frequency (observed/expected overlap in base pairs) of
each chromatin state within signiﬁcant differentially enriched sites for SMARCA2/4
(Ts65Dn vs. euploid). Chromatin states were obtained from brain regions included

in the Roadmap Epigenomics Project. d Bubble plots of GO terms (burgundy) and
KEGG pathways (purple) displaying enrichment for rescued differentially enriched
PCGs identiﬁed in b above. e Odds ratio analysis of overlapping differentially
accessible sites in Ts65Dn vs. euploid animals and Ts65Dn;Brwd1+/– animals, separated by direction of regulation. f Odds ratio analysis of overlapping PCGs displaying rescued differential SMARCA2/4 enrichment in Ts65Dn vs. euploid animals
vs. PCGs displaying differential neuronal chromatin accessibility in Ts65Dn vs.
euploid mice that are either rescued, or not, in their differential accessibility in
Ts65Dn;Brwd1+/– animals. Insert numbers indicate respective p values for associations, followed by the number of PCGs overlapping per category. See Supplementary Information Materials for full caption with n’s and statistics. Source data
are provided as a source data ﬁle.

accessibility, indicating that BRWD1-mediated BAF mistargeting is
associated with dysregulated chromatin structure (Fig. 4f).

sufﬁcient to precipitate DS-related impairments in cognition, synaptic
physiology, and gene expression in Ts65Dn mice – deﬁcits which were
rescued by genetic renormalization of Brwd1 copy number. We
showed that BRWD1 stably interacts with the BAF complex in
embryonic and adult brain and contributes to BAF mistargeting in
adult Ts65Dn hippocampus. Approximately ~60% of BAF peaks were
altered in trisomy, with many of these BAF binding events being

Discussion
In this study, we characterized roles for the epigenetic regulator,
HSA21-encoded BRWD1, in DS-related phenotypes. Our ﬁndings
demonstrated that elevated Brwd1 expression is both necessary and
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retargeted from promoters and poised genic regions towards intergenic regions of the genome. BAF mistargeting was associated with
changes in transcription and chromatin accessibility, implicating
alterations in chromatin remodeling as a causative factor underlying
DS-related impairments. Restoring Brwd1 copy number rescued ~27%
of BAF mistargeting in Ts65Dn hippocampus, indicating that BRWD1 is
an important determinant of BAF genomic localization in brain.
We hypothesize that BRWD1 may act as a substoichiometric
component for a subset of BAF complexes in brain, in that it functions
as a histone-targeting protein for a certain fraction of total BAF
(including both npBAF and nBAF) in a context-speciﬁc manner. Its
substoichiometric relationship to BAF is supported by its dosagedependent effects on BAF targeting, the fact that Brwd1 deletion does
not affect BAF assembly or mass on a glycerol gradient, and BRWD1’s
lower protein expression in mouse brain relative to other BAF
subunits36. The observation that BAF was targeted away from “active”
histone marks in trisomy does not necessarily mean that repressed
regions are the primary target of BRWD1 in euploid neurons. In fact,
BRWD1’s bromodomain 2 was found to bind to transcriptionallyactivating H3K14 and K18 acetylation in vitro37, and its WD-repeat
domain shares >84% identity with that of WDR5, which “reads” H3K4 as
part of the MLL complex38–40. Whether BRWD1 directly binds histone
modiﬁcations in brain, which histone marks it may bind to, and if its
putative histone binding activity may contribute to BAF mistargeting
in trisomy remain to be determined.
While no mouse model can fully recapitulate the complexity of
the human DS disease state, the Ts65Dn line is unique amongst other
commonly used DS models in that it carries triplicated MMU16 genes
on a separate, freely segregating chromosome, vs. other models such
as DP(16)1/Yey or Ts1Cje that harbor the HSA21-orthologous triplication as an extension or replacement on existing chromosomes41. Critically, this extra chromosome phenocopies the genomic instability
caused by autosomal aneuploidy found in human DS, in addition to the
HSA21 gene triplication. A recent study comparing three DS mouse
models found that Ts65Dn exhibited features that most closely
resembled the human symptomatic arc—particularly during embryonic time points, when Ts65Dn shows alterations in neuroanatomical
features, cytoarchitecture (e.g., neocortical expansion/neurogenesis)
and aberrant gene expression—while neither DP(16)1/Yey or Ts1Cje
exhibited major prenatal symptoms41. Furthermore, in adults, Ts65Dn
mice were found to display the most altered behavioral responses in
hippocampal-dependent tasks and gene expression41. Interestingly,
Ts65Dn males exhibited more profound developmental deﬁcits and
behavioral changes in adults compared with females, which paralleled
aspects of sex differences observed in individuals with DS41–44, as well
as the sex differences observed in the current study. One notable
drawback of the Ts65Dn model is that the additional MMU16 chromosome also contains the centromeric region of MMU17, including
~30 non-HSA21 orthologous PCGs. This complication of the Ts65Dn
model highlights the importance of our experimental design utilizing a
speciﬁc gene rescue approach that maintains the Ts65Dn trisomic
genetic background in order to more precisely determine if non-HSA21
genes are driving the deﬁcits observed in these mice.
Interestingly, in female Ts65Dn mice, we found that Brwd1 levels
are more modestly increased vs. euploid controls and exhibit greater
variability in displaying Brwd1 increases in comparison to males.
Notably, BRWD1 has been previously shown to display sex-speciﬁc
functions and expression levels, particularly in the context of early
reproductive cell genesis11. Past studies have demonstrated that, in
females, the effects of altered levels of HSA21 (e.g., Dyrk1a) may be
mitigated by buffering mechanisms involving ncRNAs and other
compensatory pathways45. Furthermore, while contextual fear learning
depends, in part, on neural plasticity in the hippocampus, we were
surprised to ﬁnd that hippocampal LTP was only impaired in male
Ts65Dn mice—an effect that was rescued by Brwd1 normalization.
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Consistent with this ﬁnding, our RNA-seq analyses directly comparing
female vs. male Ts65Dn mice found that the most signiﬁcant DE genes
between the sexes in trisomy were associated with LTP. Furthermore,
previous studies have found that male Ts65Dn mice have more severe
hippocampal deﬁcits than female mice, and that environmental
enrichment improves female but not male Ts65Dn performance in
spatial memory tasks24. In adult humans with DS, neurological symptoms are similar between males and females; however, male children
with DS have been reported to display more externalizing behavioral
deﬁcits, including attention problems, thought problems, delinquent
behavior and aggressive behavior46. Our results suggest that the
mechanisms underlying cognitive impairments in Ts65Dn mice—and
perhaps in DS individuals—may be different for males and females.
Additionally, it is important to consider that BRWD1 is not the only
epigenetic regulator encoded on HSA21. Elevated expression of
another HSA21-encoded gene, DYRK1A, has been observed in rodent
models of DS and has been implicated in DS phenotypes4,47. Like
BRWD1, DYRK1A overexpression can impair cognition in mice48, and
restoring Dyrk1a to euploid copy number (or pharmacologically inhibiting it) can rescue DS-related cognitive impairments49,50, skeletal
abnormalities51,52 and Alzheimer’s disease related phenotypes in trisomic mice53. Since BRWD1 and DYRK1A overexpression have strikingly similar effects on cognition, we hypothesize that they may
function in the same pathway. DYRK1A also been shown to participate
in BAF activity, most likely via its kinase activity. In support of this
possibility, a study of phosphoproteins that showed treatment with a
DYRK1A kinase inhibitor in Ts65Dn brain rescued altered phosphorylation of BAF complex subunits48. Importantly, our data suggest that
BRWD1 may also contribute to BAF function through its binding to
histone modiﬁcation marks, thereby guiding the genomic targeting of
BAF to facilitate chromatin restructuring. Therefore, our ﬁndings
support a model in which BRWD1 renormalization may rescue the
effects of BAF dysregulation, despite high levels of DYRK1A. How
BRWD1 may genetically interact with DYRK1A or other HSA21-encoded
proteins to regulate cognition is an important avenue for future
research. In future studies aimed at validating and investigating DSrelated mechanisms in models for human brain development, such as
cerebral organoids, it will be important to evaluate the effects of single
allele mutations for key HSA21 genes (e.g., BRWD1) in DS patientderived systems and examine DS-related molecular signatures for
evidence of genetic contributions and interactions in DS.
In conclusion, we demonstrated that a previously uncharacterized
binder of the BAF complex, BRWD1, is critically involved in regulating
aberrant neuronal gene expression patterns in DS-like brain, which
precipitate synaptic and cognitive deﬁcits associated with this disorder. Increased Brwd1 expression results in BAF genomic mistargeting, inappropriate patterns of chromatin accessibility and
dysregulated gene expression contributing to aberrant plasticity.
Gaining a better understanding of BRWD1’s precise functions within
the BAF complex, as well as its potential histone “reader” activities, will
greatly improve our knowledge of the molecular underpinnings of DS.

Methods
Cell culture
hiPSCs, NPCs, and neurons. Reprogrammed, de-identiﬁed ﬁbroblasts
from one mosaic Trisomy 21 (Ts21) patient (line AG05397)—yielding
Ts21 hiPSCs and an isogenic control—were provided by Dr. Anita
Bhattacharyya (UW–Madison) and were generated and karyotyped, as
previously described6. Rosettes were cultured in NPC medium (DMEM/
F12, 1x N2, 1x B27-RA (Life Technologies), 1 μg ml−1 Laminin
and 20 ng ml−1 FGF2) and dissociated in TrypLE (Life Technologies) for
3 min at 37 °C. NPCs were maintained at high density, grown on polyornithine/laminin or Matrigel (BD) coated plates in NPC medium
and split approximately 1:4 every week with Accutase (Life
Technologies)54,55. For neuronal differentiations, NPCs were
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dissociated with Accutase and plated in neural differentiation medium
(DMEM/F12, 1× N2, 1× B27-RA, 20 ng ml−1 BDNF (Peprotech), 20 ng ml−1
GDNF (Peprotech), 1 mM dibutyryl-cyclic AMP (Sigma), 200 nM
ascorbic acid (Sigma) onto poly-ornithine /laminin-coated plates and
matured for 4 weeks.
ANIMALS. All mice used in DS related studies exist on a mixed genetic
background, with comparative groups (euploid vs. Brwd1+/– vs. Ts65Dn
vs. Ts65Dn;Brwd1+/–) maintained on the same mixed background (DBA/
2J x B6EiC3Sn/J) for experimental testing. Brieﬂy, trisomic Ts(176)65Dn
(Ts65Dn) females (Jackson Labs Stock 001924) were crossed to
B6EiC3Sn/J (Stock 001875) euploid males to generate euploid and
Ts65Dn animal littermates for initial Brwd1 expression analyses.
Brwd1repro5 mutant mice (Mouse Genome Informatics [MGI] ID
3512929)11 were kindly provided by Dr. John Schimenti (Cornell). Heterozygotic Brwd1repro5 mutant male mice, aka Brwd1+/– (fully backcrossed > 10 generations to B6EiC3Sn/J to match the breeding scheme
for euploid vs. Ts65Dn animals), were crossed to Ts65Dn females to
generate euploid vs. Brwd1+/– vs. Ts65Dn vs. Ts65Dn;Brwd1+/– animals
for genetic rescue experiments. All animal protocols were approved by
the IACUC at the Icahn School of Medicine at Mount Sinai (ISMMS).

Generation of Brwd1FLAG-HA mice by CRISPR/Cas9 genome editing
Given that suitable antibodies for the detection of endogenous Brwd1
in rodent tissues are not commercially available, we generated
Brwd1FLAG-HA mice for in vivo interrogations. An optimal guide sequence
was selected using online software at mit.crispr.edu. The selected
guide RNA sequence corresponding to Brwd1 was as follows:
CAGCCTACTCCGAGG. The DNA template for making sgRNA was
generated using a cloning-free overlap PCR method, essentially as
described56. The DNA template was reverse transcribed into RNA using
an Ambion MEGAshortscript T7 Transcription Kit (cat#AM1354), then
puriﬁed using Qiagen MinElute columns (cat#28004). For pronuclear
injection, the sgRNA (50 ng/μL), ssODN (50 ng/μL, IDT Ultramer Service), and Cas9 mRNA (25 ng/μL, TriLink) were co-injected into zygotes
(F1 hybrids between strains FVB/NJ and B6(Cg)-Tyrc-2J/J) then transferred into the oviducts of pseudopregnant females. Founders carrying at least one copy of the desired alteration were identiﬁed and
backcrossed into FVB/NJ. Initial phenotyping was done after one
backcross generation, and additional phenotyping was done with mice
backcrossed at least two or more generations (Supplementary Fig. 10).
PURPOSE

SEQUENCE (5′ to 3′)

ssODN with 1xFLAG
and 1xHA

CRISPR/Cas9

ATCTTAGGCGGTTCAG
ATCCCGGAAGGAAAAAGCCC
AGCCTACTCCGAGG
GACTACAAA
GACGATGACGACA
AGGGGTATCCCTATG
ACGTCCCGGACTATGCA
TAGAAAGGTTACCGGG
AATTGTCAGCAGCTCC
AATGCCTGCCCTGAAGTC

sgRNA Template (T7
Forward)

CRISPR/Cas9

GAAATTAATACGACTCACTAT
AGGCAGCCTACTCCGAGGTA
GAAGTTTTAGAGCTA
GAAATAGC

sgRNA Template (T7
Reverse)

CRISPR/Cas9

CAAAATCTCGATCTTT
ATCGTTCAATTTTATTCCGAT
CAGGCAATAGTTGAACT
TTTTC
ACCGTGGC
TCAGCCACGAAAA

Brwd1 Common Primer (Forward)

Genotype,
RT-qPCR

TGCATAGTGACACCCTGAAAG

Brwd1 Common Primer (Reverse)

Genotype,
RT-qPCR

3′-GCTGTGTAGAGCTAACTGGAAG-5′
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Epitope-Speciﬁc Primer (Reverse)

RT-qPCR

3′-TCCGGGACGTCATAGGGATA-5′

Brwd1 repro5 Primer
(Forward)

Genotype

ATGGCCACTGTAGGTTCAGC

Brwd1 repro5 Primer
(Reverse)

Genotype

TTAAAGTCCACGACCCCTGA

Sequences of primers and oligonucleotides
Brwd1FLAG-HA genotyping. Crude lysates for PCR were made from small
tissue biopsies (tail, toe or ear punches). Genotyping primers are listed
above. PCR reactions were carried out as follows: initial denaturation at
95° for 5 min, then 30 cycles of 95° for 30 s, 58° for 30 s, 72° for 30 s,
and a ﬁnal elongation at 72° for 5 min. For identiﬁcation of Brwd1FLAG-HA,
amplicons were analyzed on high percentage agarose gels. The WT
allele yields a band at 454 bp, and the FLAG-HA allele yields a band
at 508 bp.
Housing and oversight
Mice were group housed (separated by sex)—with the exception
of surgerized animals, which were singly housed post-surgery—under a
12-h-light/dark cycle at constant temperature (25 °C) and humidity
with ad libitum access to food and water. Animals arriving from
external sources were allowed at least one week of habituation to
housing conditions prior to experimentation. Both male and female
mice were assessed in these studies [embryonic/E17.5 (mixed male and
female) and adult (6-week, males and females analyzed separately). All
procedures were performed in accordance with NIH guidelines and the
Institutional Animal Use and Care Committees (IACUC) at the Icahn
School of Medicine at Mount Sinai, Michigan State University and
Cornell University.

RNA isolation and qPCR
hiPSC neurons were collected following differentiation (4 weeks) and
pellets were immediately homogenized in RLT buffer (Qiagen). Forebrain from E17.5 embryos, and whole mPFC, hippocampus and cerebellum were collected from 6-week-old mice and ﬂash frozen. For
validation of Brwd1 overexpression in viral transduction experiments,
mice were euthanized 4 days following viral infusion and brains were
ﬂash frozen. Infected brains were then sectioned at 100 μm on a
cryostat and GFP was illuminated using a NIGHTSEA BlueStar ﬂashlight
to microdissect virally transduced tissues. All tissues were homogenized in Trizol (Thermo Fisher). RNA was isolated on RNeasy
Microcolumns (Qiagen) following the manufacturer’s instructions.
RNA was then reverse transcribed using iScript (BioRad cat# 1708891)
and cDNA was quantiﬁed by qPCR using SYBR Green (Qiagen). Each
sample was run with technical replicates and gene expression fold
changes were calculated using the ΔΔCt method normalized against
the housekeeping gene GAPDH/Gapdh. For Brwd1 rescue validations,
Brwd1_3′ primers were used, and for all other mouse assessments,
Brwd1 primers were used. Sequences of qPCR primers (forward and
reverse) used are as follows:
Mouse
GapdhF: AGGTCGGTGTGAACGGATTTG
GapdhR: TGTAGACCATGTAGTTGAGGTCA
Brwd1_3′F: GCCTGGTGTTCAGATGCTGTG
Brwd1_3′R: GCTGTTCCATCTCGGCTACCA
Brwd1F: TGAGTGATGCAGAGGATTCG
Brwd1R: TGCTGTTGTGGACAGAATGG
FosF: GAACGGAATAAGATGGCTGC
FosR: TTGATCTGTCTCCGCTTGG
Npas4F: CTGCATCTACACTCGCAAGG
Npas4R: GCCACAATGTCTTCAAGCTCT
Zif268F: ACCACAGAGTCCTTTTCTGAC
Zif268R: AAGCGGCCAGTATAGGTGATG
BdnfF: TCAGCAGTCAAGTGCCTTTG
BdnfR: TCAGTTGGCCTTTGGATACC
9
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Human
GAPDHF: AATCCCATCACCATCTTCCA
GAPDHR: TGGACTCCACGACGTACTCA
BRWD1F: AGCCCTTTGCACTCGTTATG
BRWD1R: GGGTTTCAGTTGGCACAATC
For initial validations of the Brwd1FLAG-HA line, testes were harvested
from 8-week-old wildtype, heterozygous and homozygous tagged
mice, and tissues were homogenized. In brief, total RNA was extracted
and puriﬁed using Trizol following the manufacturer’s instructions.
Next, 1.5ug of RNA from each condition was reverse transcribed into
cDNA using qScript cDNA SuperMix kit (Quantabio; cat# 101414-102).
The resulting cDNA was used as a template and combined with Fast
SYBR Green Master Mix (Life Technologies) for qPCR. Custom primers
were designed using Primer3 and are listed in the Table above. Assays
were run on a CFX96 TouchTM Real-Time PCR Detection System (BIORAD), where each sample was run in triplicate. The Ct values were
obtained and averaged per triplicate reaction and then normalized
to GAPDH.

Immunocytochemistry
Human cells were ﬁxed in 4% paraformaldehyde in PBS at 4 °C for
10 min, permeabilized at room temperature for 15 min in 0.1% Triton in
PBS and then blocked in 5% donkey serum with 0.1% Triton at room
temperature for 30 min. The following primary antibodies and dilutions were used: goat anti-NANOG (R&D), 1:200; mouse anti-TRA1-60
(Chemicon), 1:100; mouse anti-human NESTIN (Chemicon), goat antiSOX2 (Santa Cruz), 1:200; rabbit anti-βIII-tubulin/Tuj 1 (Covance),
1:200; mouse anti-MAP2AB (Sigma), 1:200. Secondary antibodies used
include Alexa donkey 488 and 568 anti-rabbit (Life Technologies),
Alexa donkey 488 and 568 anti-mouse (Life Technologies), and Alexa
donkey 488 and 568 anti-goat (Life Technologies); all were used at
1:300. To visualize nuclei, slides were stained with 0.5 μg ml−1 DAPI
(4′,6-diamidino-2-phenylindole) and then mounted with Vectashield.

Field electrophysiology
Acute slices were prepared from 6-week-old mice, as previously
described57,58. Brieﬂy, mice were deeply anesthetized with isoﬂurane,
and their brains were rapidly removed and immersed in an ice-cold
modiﬁed ACSF solution containing: 215 mM sucrose, 2.5 mM KCl,
1.6 mM NaH2PO4, 4 mM MgSO4, 1 mM CaCl2, 4 mM MgCl2, 20 mM
glucose, and 26 mM NaHCO3 (pH = 7.4, equilibrated with 95% O2/5%
CO2). Coronal brain slices (400-µm thick) containing the hippocampus
were prepared with a vibrating slicer (VT1000S; Leica Microsystems)
and then incubated at room temperature for ≥3 h in physiological
ACSF, containing (in mM): NaCl (120), KCl (3.3), Na2HPO4 (1.2), NaHCO3
(26), MgSO4, (1.3) CaCl2 (1.8) and glucose (11), equilibrated to pH 7.4
with 95% O2 and 5% CO2. Hemi-slices were transferred to a submersion
recording perfused with ACSF at a ﬂow rate of ~2 mL/min using a
peristaltic pump; experiments were performed at 28.0 ± 0.1 °C.
Recordings were acquired with a GeneClamp 500B ampliﬁer and
Digidata 1440A digitizer (Molecular Devices), with all signals low-pass
ﬁltered at 2 kHz and digitized at 10 kHz. Field excitatory postsynaptic
potentials (fEPSPs) were recorded with a patch-type pipette ﬁlled with
ACSF (Re = 2–3 MΩ), positioned in the middle third of stratum radiatum in area CA1. fEPSPs were evoked by 60-µs square-wave monophasic stimuli generated by an ISO-Flex stimulus isolator (A.M.P.I.) and
delivered to the Schaffer collaterals by a concentric bipolar electrode
(FHC) positioned in the middle third of stratum radiatum, 150–200 µm
away from the recording pipette. Input-output curves were generated
by a series of stimuli in 0.1-mA steps. Paired-pulse ratios (PPR) were
determined by delivering two stimuli at intervals of 20, 50, and 100 ms;
each interstimulus interval was repeated three times, and the resulting
potentials were averaged. PPR was calculated as slope of the second
fEPSP divided by slope of the ﬁrst fEPSP. Long-term potentiation (LTP)
was induced after 20 min of stable baseline recordings (at 0.033 Hz) by
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theta-burst stimulation (TBS), which consisted in a series of 10 bursts
of 4 stimuli (100 Hz within the burst, 200-ms interburst interval),
repeated four times (10 s apart), and delivered at a stimulus intensity
that produced a baseline response of 75% of spike threshold. Following
TPS, stimulation at 0.033 Hz resumed for 60 min. All results were
analyzed by ANOVAs followed, where appropriate, by Tukey posthoc tests.

Patch electrophysiology
All recordings were carried out blind to the experimental conditions.
Male C57BL/6 3-month-old mice were injected intra-CA1 with either
HSV-GFP or HSV-BRWD1-GFP. After 4–5 days of expressing HSV-GFP
vs. HSV-BRWD1-GFP, mice were perfused with cold artiﬁcial cerebrospinal ﬂuid (aCSF) containing (in mM): 128 NaCl, 3 KCl,
1.25 NaH2PO4, 10 D-glucose, 24 NaHCO3, 2 CaCl2, and 2 MgCl2 (oxygenated with 95% O2 and 5% CO2, pH 7.35, 295–305 mOsm). Acute
brain slices containing CA1 were cut using a microslicer (DTK-1000,
Ted Pella) in sucrose-ACSF, which was derived by fully replacing NaCl
with 254 mM sucrose, and saturated by 95% O2 and 5% CO2. Slices
were maintained in the holding chamber for 1 h at 37 °C. Slices were
transferred into a recording chamber ﬁtted with a constant ﬂow rate
of aCSF equilibrated with 95% O2/5% CO2 (2.5 ml/min) and at 35 °C.
Glass microelectrodes (2–4 MΩ) ﬁlled with an internal solution containing (mM): 115 potassium gluconate, 20 KCl, 1.5 MgCl2, 10 phosphocreatine, 10 HEPES, 2 magnesium ATP and 0.5 GTP (pH 7.2,
285 mOsm). All recordings were performed in GFP labeled cells
located in the CA1 pyramidal layer. Cell excitability of CA1 neurons
expressing GFP was measured with 2 s incremental steps of current
injections (50, 100, 150, and 200 pA) at −70 mV holding potential.
Series resistance was monitored during all recordings at the beginning and end of each recording, and data were rejected if values
changed by more than 20%. All data acquisition and on-line analysis
were collected using 700B ampliﬁer, Digidata 1322 A digitizer, and
pClamp 10.2 (Molecular Devices). Spontaneous excitatory postsynaptic currents (sEPSCs) were recorded in voltage clamp at a
holding potential of −70 mV with series resistance of <6 MΩ, in the
presence of picrotoxin (50 μM). For recording sEPSCs, the external
aCSF solutions contained 50 μM dl-2-amino-5-phosphonovaleric acid
(AP-5) to block NMDA receptors. The ionic composition of the
internal (pipette) solution for voltage-clamp studies of sEPSC consisted of (in mM) 140 CsCl, 10 phosphocreatine, 2 MgCl2, 10 EGTA,
2 magnesium ATP and 0.5 GTP and 10 HEPES with a pH adjusted with
CSOH. sEPSC was analyzed with the MiniAnalysis software (Synaptosoft). Brieﬂy, sEPSCs were detected automatically using an amplitude threshold of 10 pA and then visually accepted or rejected based
upon the rise and decay times. Spontaneous inhibitory postsynaptic
currents (sIPSCs) were recorded in aCSF containing kynurenic acid
(3 mM), with the holding potential set at 0 mV. To compute the
average sIPSCs, the synaptic events with single-peaks were aligned
with the rise time. The amplitude of GABA-activated tonic current
was measured as the difference in the baseline holding current
before and after the application of bicuculline.

Behavior
Fear conditioning (FC). Mice (6–8 weeks old) were habituated to the
testing room for 20 min prior to training. Mice were then trained over
three conditioning trials, each consisting of random intervals with a
2.0-s, 0.6-mA foot shock. Training in context A was conducted in a dark
room with white noise. Context A chambers consisted of a square
plexiglass chamber with metal rods (which delivered the shock during
training), and the ﬂoor had been washed with 70% ethanol. Context B
(no training) was conducted in white light with no noise and consisted
of a cylinder plexiglass chamber with a ﬂat white plastic ﬂoor that had
been washed with Micro-90. Context B chambers had a solution of 10%
vanilla extract placed next to them.
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Testing for conditioned fear responses (freezing) to the trained
context occurred 24 h following training. Mice were equally divided
and placed into either Context A or Context B for 5 min and total
seconds of freezing were recorded (EthoVision). Mice were then
exposed to the opposite context 4 h following the ﬁrst testing session
and freezing was recorded. Freezing was expressed as a percentage of
the total test time.
Temporally dissociated passive avoidance (TDPA). Passive avoidance learning was assessed in mice, modiﬁed from a published
protocol59. For conditioning, mice were placed into the lighted side of
a divided light-dark chamber (Coulbourn Instruments). After 1 min, the
entry door to the dark side was raised and latency to crossover to the
dark side was recorded. Entry was deﬁned as whole body, including all
four paws and tail base, on the dark side. Upon an entry, the door was
closed. 30 s later, mice were administered a mild electric footshock
(0.8 mA, 2 s duration), and following another 30 s, mice were returned
to their home cage. Mice were tested the following day. Testing was
conducted in the same manner as conditioning. When a criterion of
300 s spent in the light side was reached, a mouse would be returned
to its home cage.
Open ﬁeld. For locomotion and anxiety-like behaviors, mice were
placed in an open ﬁeld apparatus (Omnitech Electronics, Inc.,
Columbus, OH), which consisted of a 16 × 16-in. plastic chamber surrounded by 16 photobeam detectors along the x- and y-axis to measure
horizontal movement. Mice were placed in the open ﬁeld apparatus for
30 min and distance and time in center vs. periphery were recorded.
Behavior was analyzed using Fusion software (Version 5.6, Omnitech
Electronics, Inc.).
Elevated plus maze (EPM). Anxiety-like behavior was assessed in mice
conducted using the EPM test60. Mice acclimated to the maze room for
30 min prior to testing. During testing, mice were placed into the
center of the maze and allowed to explore for 5 min before being
placed back into their home cage. Behavior was measured using
automated videotracking software (CleverSys, Inc.).
Sucrose preference. A 2-bottle choice test protocol was used for
assessing sucrose preference61. Mice were single-housed for 24 h prior
to testing and then throughout the experiment. Custom bottles (2 per
cage) containing RO water were ﬁrst placed into the cages for 4 days
for a baseline assessment of bottle preference. For the testing period,
one of the bottles was replaced with a 2% sucrose solution in RO water
for 4 more days. Bottle weights were measured daily every morning
(9 A.M.) throughout the experiment, switched sides (left or right side
of cage top) daily, and preference for the sucrose-containing bottle
was assessed.
Morris water maze (MWM). Water maze testing was conducted as
previously described60. Brieﬂy, swim behavior was measured in a water
pool ﬁlled with white beads and a platform. Prior to surgeries, to
acclimate mice to the water maze, animals were trained to ﬁnd a visible, cued platform randomly placed at different locations for six 60 s
trials. After surgeries, training was conducted across 4 daily trials (1 h
intertrial intervals) for 5 days to locate a hidden platform. Trials lasted
60 s or when the mouse reached the platform, whichever came ﬁrst.
24 h after the last day of training, a 60 s probe test was conducted,
where the platform was removed. Trial latency and swim speed (cm/s)
were recorded during both training and testing. Quadrant time was
recorded during the probe test.

Generation of HSV viral constructs
The mouse BRWD1-FLAG-HA coding sequence was subcloned into the
bicistronic p1005+ HSV plasmid expressing GFP under the control of
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the human immediate early cytomegalovirus promoter (CMV). An IE4/
5 promoter drives BRWD1-FLAG-HA expression. HSV-GFP vectors were
used as controls in behavioral experiments. Viral constructs were
packaged at the Gene Technology Core (Massachusetts General
Hospital).
We used HSV vectors in our studies of sufﬁciency for the following
reasons: 1) HSVs solely infect neuronal cell bodies within an injected
region of brain; 2) HSV-encoded transgenes are expressed very rapidly
(within 12 h) but only transiently (they dissipate within 7 days); and 3) it
was necessary to use HSV vectors to express BRWD1, since the Brwd1
gene far exceeds the maximum insertion size for other neuronal speciﬁc vectors, such as AAVs. While complementary to our copy number
restoration studies, the expression of Brwd1 per HSV-infected neuron
likely exceeds that of the trisomic context, a phenomenon that should
be considered when comparing phenotypes arising from the two
manipulation strategies.
Novel environment (NE). For immediate early gene (IEG) qPCR
assessments in Fig. S4A, microdissected tissues from mice transduced
with HSV-GFP vs. HSV-BRWD1-GFP (CA1) were collected from animals
either in their home cage (HC) or after being moved to a NE for 30 min
vs. 90 min.

Stereotaxic surgery and viral delivery
Animals were anaesthetized with a ketamine/xylazine solution (100/
10 mg/kg) i.p. and then positioned in a stereotaxic frame (Kopf
instruments). HSV-BRWD1 or HSV-GFP were bilaterally infused (0.5 µL
at 0.1 µL/min; 7° angle) into dorsal hippocampus using the following
coordinates: −2.2 AP, ±2.0 ML, −2.0/−1.8 mm from bregma. All tissue
collections and/or behavioral experiments commenced 24 h to 4 days
after surgery.

Immunohistochemistry (IHC)
For viral Brwd1 overexpression studies, mice were anesthetized with a
ketamine/xylazine solution (100/10 mg/kg) 4 days following viral infusions and transcardiacally perfused with cold phosphate-buffered saline
(PBS)/4% paraformaldehyde (PFA). Brains were post-ﬁxed overnight
(~12 h) in 4% PFA and then cryoprotected in 30% sucrose/PBS 1× for
2 days at 4 °C. Brains were sectioned at 40 μm on a cryostat. Brain
sections were then incubated overnight at room temperature with primary antibodies. Antibodies used for hippocampal brain sections: antichicken GFP. The following day, brain sections were washed 3× in 1× PBS
and then incubated for 2 h at room temperature with a ﬂuorescenttagged Alexa Fluor antibodies, washed 3× in 1× PBS and then incubated
with DAPI (1:10,000) for 5 min at room temperature. Brain sections were
then mounted onto slides with Prolong Gold and immunoﬂuorescence
was visualized using a confocal microscope (Zeiss LSM 780).
Double labeling of HA-tag with DDX4 in mouse testis. 4-μm–thick
sections of paraformaldehyde-ﬁxed/parafﬁn-embedded mouse testis
were used for immunohistochemical analyses. After deparafﬁnization
in xylene and rehydration in graded ethanol, heat-activated antigen
retrieval was performed in Tris-EDTA (pH9.0) for 20 min. Endogenous
peroxidase activity was quenched with 0.3% hydrogen peroxide in
distilled water for 10 min. The HA-tag and DDX4 IHC detections were
performed using an ImmPRESS HRP Anti-Rabbit Ig (Peroxidase) Polymer Detection Kit and an ImmPRESS™-AP Anti-Rabbit IgG (alkaline
phosphatase) Polymer Detection Kit, respectively (Vector Laboratories), following the kit instructions. Rabbit anti-HA-tag antibody was
used at 1:50 and labeled with DAB, while rabbit anti-DDX4 was used at
1:1000 and labeled with Red substrate. Finally, tissues were counterstained with hematoxylin and mounted with Permount. IHC results
were examined by Olympus AX 70 compound microscope equipped
with MicroFire camera and PictureFrame for image processing and
capture (Optronics).
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Primary cortical neuronal culture
Pregnant female mice were euthanized and cortices from E16
embryos were dissected. Tails from each embryo were collected for
genotyping. Cortices were incubated individually in trypsin-EDTA
(0.25%; Gibco) for 10 min to dissociate and neurons were plated at
0.6 million cells per well in six-well Poly-D-Lysine (Sigma) coated
plates in DMEM (Gibco) containing 10% fetal bovine serum and 1%
penicillin–streptomycin. The following day, the medium was
changed to a serum-free medium containing neurobasal and B27
(Gibco) and AraC to inhibit glial cell proliferation. Half media
changes occurred every 4 days. Cells were maintained at 37 °C, 5%
CO2, and 95% humidity. Cells were collected at DIV12 for RNA
sequencing.

RNA-SEQ library preparation and sequencing
Following RNA puriﬁcation with trizol and the Qiagen RNAeasy Minelute kit (Cat.# 74204), libraries were prepared using the TruSeq RNA
Library Prep Kit v2 according to Illumina protocols, multiplexed library
sizes were validated on an Agilent Bioanalyzer system and then
sequenced (single-read) on an Illumina HiSeq 4000 or Illumina NovaSeq 6000 sequencer.

RNA-SEQ analyses
Raw sequencing reads from mouse embryonic forebrain, e17.5 primary
neuronal cultures, or adult hippocampus were mapped to mm10 using
HISAT2(Version 2.2.1 + galaxy0)62. Counts of reads mapping to genes
were obtained using featureCounts(v2.0.1 + galaxy2)63 against Ensembl
v90 annotation. Read counts were normalized using RUVr (v1.24.0),
and differential expression analysis was done using the DESeq2 package (v1.6.3)64—for both likelihood-ratio-test and pairwise comparisons
—at FDR cutoffs of 0.1. GO analyses were conducted using iDEP[Ge,
2018 #12]. Odds ratio analyses between DE gene lists and human DS
RNA-seq20 were conducted based on gene names using geneOverlap
(GeneOverlap: Test and visualize gene overlaps. R package version 1.23.0.

Experiments related to BAF-BRWD1 complex associations
Ammonium sulfate precipitation of soluble brain nuclear proteins.
Adult or E17.5 mouse brains were extracted, ﬂash-frozen in liquid
nitrogen and stored at −80 °C. Brains were thawed in 10 mL of ice-cold
Buffer A [10 mM HEPES, pH 7.5, 25 mM KCl, 1 mM EDTA, 0.1% NP40,
10% glycerol, plus 1 mM DTT, protease inhibitor tablet (Roche), 1 mM
sodium orthovanadate, and 10 mM sodium butyrate freshly added at
time of use]. Nuclei were released from cells by douncing brain tissues
with ten strokes of a loose-ﬁtting pestle, followed by ten strokes with a
tight-ﬁtting pestle on ice. The lysates were then centrifuged at 1700 × g
for 10 min at 4 °C to pellet nuclei. The nuclei were washed 2× with 5 mL
ice-cold Buffer A and then washed 1× in 3 mL Buffer C [10 mM HEPES
pH 7.5, 100 mM KCl, 1 mM EDTA, 3 mM MgCl2, 10% glycerol plus 1 mM
DTT, protease inhibitor tablet (Roche), 1 mM sodium orthovanadate,
and 10 mM sodium butyrate freshly added at time of use]. The
supernatant was removed from the pelleted nuclei and the volume was
adjusted to 2.8 mL exactly with Buffer C. The resuspended nuclei were
then divided evenly into four 1.5 mL microcentrifuge tubes. To each
700 μL of resuspended nuclei, 77.7 μL of 3 M ammonium sulfate was
added drop-wise to lyse nuclei and salt out the DNA. The solutions
were rotated at 4 °C for 30 min to overnight (overnight worked slightly
better). DNA was pelleted by ultracentrifugation (Beckman Coulter) at
100,000 rpm for 15 min at 4 °C. The supernatant containing soluble
nuclear proteins was transferred to a clean 1.5 mL microcentrifuge
tube and 233 mg of solid ammonium sulfate was added to precipitate
soluble nuclear proteins. The mixture was rotated for 20 min to
overnight at 4 °C. The precipitated nuclear proteins were pelleted by
ultracentrifugation at 100,000 rpm for 20 min at 4 °C. Pelleted nuclear
proteins from brain tend to ﬂoat on top of the buffer and so the buffer
Nature Communications | (2022)13:6384

https://doi.org/10.1038/s41467-022-34200-0

must be carefully removed. Nuclear extracts (4 tubes/brain) were then
stored at −80 °C.
Density sedimentation (10–30% glycerol gradient). Brain nuclear
extract from one quarter to half of an adult mouse brain (wild type,
Brwd1−/− or Brwd1FLAG-HA) was resuspended in 220 μL ice cold HEMG-0
buffer (50 mM HEPES pH 7.9, 100 mM KCl, 0.1 mM EDTA, 12.5 mM
MgCl2, plus 1 mM DTT, protease inhibitor tablet (Roche), 1 mM sodium
orthovanadate, and 10 mM sodium butyrate freshly added at time of
use). Of this, 10% was reserved as input. In the meantime, a 10 mL,
10–30% gradient of glycerol in HEMG buffer was poured into a
14 × 89 mm polyallomer centrifuge tube (Beckman Coulter cat. #
331372). The resuspended nuclear extract was carefully laid atop the
gradient and then centrifuged in an SW41 rotor at 40,000 rpm for 16 h
at 4 °C. Twenty 0.5 mL fractions were carefully collected and 10% of
each fraction was run on an SDS PAGE gel. Nuclear proteins were
transferred overnight (26 h was optimal for 260 kDa BRWD1) at 85 mA
(constant amperage) to a PVDF membrane and then immunoblotted
using antibodies to subunits of the BAF complex or to HA (see
Antibodies).
Co-immunoprecipitations. Antibodies raised against subunits of
the BAF complex (see Antibodies) were bound to Protein G
Dynabeads (ThermoFisher cat. # 10009D) at a ratio of 8 μg antibody: 50 μL Dynabeads per IP. The unbound antibody was
removed and the beads were washed 3× in immunoprecipitation
(IP) buffer [20 mM HEPES pH 7.5, 150 mM KCl, 1 μM CaCl2, 1 mM
MgCl2, 0.1% Triton X-100, 10% glycerol, plus 1 mM DTT, protease
inhibitor tablet (Roche), 1 mM sodium orthovanadate, and 10 mM
sodium butyrate freshly added at time of use]. Nuclear protein
pellets were resuspended in 220 μL IP buffer and the protein
concentration was determined by Bradford assay. For each IP,
250–350 μg of nuclear extract was resuspended to 0.25 mg/mL and
added to the antibody-bound beads (note that the dilute concentration of 0.25 mg/mL is critical to prevent non-speciﬁc binding
of brain proteins to the beads). The nuclear extract was rotated
overnight at 4 °C. The next day, the supernatant or “ﬂow-through”
was separated and reserved for depletion studies (see below). The
beads were washed 5× with ice cold IP buffer. Nuclear proteins
were eluted by boiling in 44 μL 1.1× LDS Sample Buffer (Invitrogen)
supplemented with β-mercaptoethanol, then separated on an SDSPAGE gel and transferred overnight (26 h ideal for BRWD1) at
85 mA (constant amperage) to a PVDF membrane. Antibodies
raised against subunits of the BAF complex or against HA (to
indicate endogenously tagged BRWD1) were used to detect
immunoprecipitated proteins.
Depletion studies. To roughly determine how much BRWD1-FLAG-HA
was associated with the BAF complex in brain, we successively
immunoprecipitated BAF complexes with α-SMARCA4, α-SS18 or αSS18L1 antibodies, or IgG as a control, three times from the same brain
nuclear extract. Speciﬁcally, the ﬂow-through from the initial IP
experiment was used as input for the second IP, and the resulting ﬂowthrough was used as input for the third IP. The ratio for each immunodepletion was approximately 1 μg antibody for each 31 μg nuclear
extract. A fraction of the ﬁnal ﬂow-through representing three immunodepletions was run on an SDS PAGE gel and transferred to a PVDF
membrane as above. Subunits of the BAF complex, BRWD1-FLAG-HA,
and control proteins (TBP and actin) were detected with speciﬁc
antibodies (see Antibodies). The intensity of protein bands was
quantiﬁed by densitometry using ImageJ. Signal remaining in the
nuclear extract after immunodepletion was normalized to the average
signal in the IgG (n = 4 biological replicates for adult, n = 3 biological
replicates for E17.5; E17.5 experiments included a rabbit IgG control for
the rabbit SS18 antibody).
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Urea denaturation. To assess the relative stability of BAF:BRWD1
interactions, nuclear extracts were subjected to partial urea denaturation. Speciﬁcally, 300 μg of nuclear extract was resuspended in
100 μL of IP buffer (+0.5 mM CaCl2) and then a freshly prepared 2×
urea solution (in IP buffer) was added 1:1 for a ﬁnal concentration of 0,
0.25, 0.5, 1, 2, or 4 M urea, respectively. The urea-nuclear extract
solutions were vortexed for 1 s at medium (“4”) speed to mix and then
incubated at room temperature for 15 min. Each 200 μL solution was
then dialyzed individually in a 3500 MWCO Slide-A-Lyzer MINI Dialysis
Unit (ThermoFisher) with two 10 mL buffer exchanges over 2 h at 4 °C.
The dialysis membrane was ruptured and all nuclear extract was
recovered by centrifugation. IP buffer was added to a ﬁnal volume of
1200 μL to achieve the optimal 0.25 mg/mL concentration of brain
nuclear extract for each IP. Nuclear proteins were immunoprecipitated
using α-SMARCA4 (BRG1 H-10 clone, Santa Cruz cat. #374197) or
mouse IgG as a control, and then run on SDS-PAGE and immunoblotted
as above.
Antibodies. Antibodies used for immunoprecipitation were: mouse
IgG (Santa Cruz cat. # sc-2025), α-SMARCA4 (BRG1 H-10, mouse
monoclonal, Santa Cruz cat. # sc-374197), α-SS18L1#1 (CREST M-15,
goat polyclonal, Santa Cruz cat. # sc-50912), α-SS18L1#2 (CREST D-7,
mouse monoclonal, Santa Cruz cat. # sc-515827), α-SS18 (SS18 D6I4Z,
rabbit monoclonal, Cell Signaling cat. # 21792), (α-SMARCC2 (BAF170
E-6, mouse monoclonal, Santa Cruz cat. # sc-17838), α-SMARCB1 (INI1/
BAF47 A-5, mouse monocolonal, Santa Cruz cat. # sc-166165), αSMARCD3 (BAF60C RN-18, mouse monoclonal, Santa Cruz cat. # sc101163; this antibody did not appear to work for IP). For immunoblotting, additional antibodies were used: α-HA (6E2, mouse monoclonal, Cell Signaling cat. # 2367; this antibody was by far the most
clean of several α-HA antibodies tested), α-SMARCA2/4 (BRG1/BRM J1
clone, rabbit polyclonal, made in-house), α-ACTL6B/BAF53B (rabbit
polyclonal, made in-house), α-ACTL6A/BAF53A (mouse monoclonal,
NeuroMab clone N336B/83), α-TOP2B (F-12, rabbit polyclonal, Santa
Cruz cat. # sc-365916), α-ARID1B (mouse monoclonal, Novus Biologicals cat. # H00057492-M01), α-PBRM1 (BAF180 D3F7O, rabbit monoclonal, Cell Signaling cat. #91894), α-TBP (mouse monoclonal, Abcam
cat. # ab818), α-Β-ACTIN (AC-15, mouse monoclonal, Santa Cruz cat.
#sc-69879). Goat or donkey, α-mouse, or α-rabbit IRDye 800CW or
680LT (LI-COR) secondary antibodies were used for Western blot
analysis with an Odyssey CLX imaging system (LI-COR).
Western blot validations of tag expression in testes (related to Fig.
S6). Testes were harvested from 8-week old wildtype, heterozygous,
and homozygous tagged mice and were homogenized in T-PER
Protein Extraction Reagent (ThermoFisher Scientiﬁc) buffer with
complete Protease Inhibitor Cocktail added (Sigma-Aldrich). Tissues were then centrifuged at 2900 RCF for 15 min at 4° to get rid of
any pelleted debris, followed by sonication with 3 × 10 s pulses.
Samples were then denatured in SDS loading buffer at 95° for 10 min
and loaded into Mini-PROTEAN Pre-cast 4–20% Gradient Polyacrylamide Gels (BIO-RAD). Protein was transferred onto a nitrocellulose membrane at 1 amp for 40 min in Bolt & Mahoney buffer.
The blot was blocked in 5% nonfat milk diluted in TBS with 0.1%
Tween20 for 1 h and incubated in anti-HA antibody (1:500) at 4° for
overnight (Roche, cat# 11867423001). Next day, the blot was
washed with TBS-Tween20 (0.1%) and incubated with goat anti-rat
IgG HRP antibody (1:5000) for 1 h at room temperature (abcam, cat#
ab97057). To detect protein, blot was incubated with Luminata
Crescendo Western HRP substrate (EMD Millipore) for 5 min and
visualized using ChemiDoc Imaging System (BIO-RAD).

Chromatin immunoprecipitation (CHIP)
Hippocampal tissues (unilateral hippocampus from two animals were
pooled/biological replicate; euploid, Ts65Dn, and Ts65Dn;Brwd1+/-, 6
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wk old) were crosslinked, quenched and processed, as previously
described65. Brieﬂy, samples were washed thoroughly, lysed and
sonicated. Samples were then incubated with a custom anti-SMARCA2/
4 antibody provided by the Crabtree lab66 (7.5 µg/sample) bound to
sheep anti-rabbit M-280 Dynabeads (Invitrogen) on a rotator at 4 °C O/
N. The following day, immunoprecipitates were washed, eluted and
reverse-crosslinked in elution buffer O/N. DNA was puriﬁed using a
PCR puriﬁcation kit (Qiagen).

CHIP-SEQ library preparation and sequencing
Following DNA puriﬁcations, libraries were prepared using the
TruSeq ChIP Library Prep Kit according to Illumina protocols,
multiplexed library sizes were validated on an Agilent Bioanalyzer
system and then sequenced (single-read) on an Illumina HiSeq
4000 sequencer.

ATAC-SEQ preparation and sequencing
Nuclei isolation for (ﬂuorescence-activated nuclear sorting) FANS.
Frozen whole hippocampus was homogenized in cold lysis buffer
(0.32 M Sucrose, 5 mM CaCl2, 3 mM Mg(Ace)2, 0.1 mM, EDTA,
10 mM Tris-HCl, pH8, 1 mM DTT, 0.1% Triton X-100) by douncing
50× in a 10 ml dounce homogenizer and ﬁltered through a 40 µm
cell strainer to isolate nuclei. The ﬂow-through was underlaid with
sucrose solution (1.8 M Sucrose, 3 mM Mg(Ace)2, 1 mM DTT, 10 mM
Tris-HCl, pH8) and subjected to centrifugation at 4000 rpm for
15 min at 4 °C to remove cellular debris. Pellets were thoroughly
resuspended in 500 µl DPBS and incubated in BSA (ﬁnal concentration 0.1%) and anti-NeuN antibody (1:1000, Alexa488 conjugated, Millipore, cat#: MAB377X) under rotation for 1 h at 4 °C in
the dark. Prior to FANS, DAPI (Sigma cat#: MBD0015) was added to a
ﬁnal concentration of 1 µg/ml. Unstained nuclei and nuclei stained
with only secondary antibody served as negative controls. DAPIpositive neuronal (NeuN+) nuclei were sorted into tubes using a BDFACSAria ﬂow cytometer (BD Biosciences) equipped with a 70 μm
nozzle.
Generation of ATAC-seq libraries. ATAC-seq reactions were performed using an established protocol67 with minor modiﬁcations.
Following FANS, 50,000 sorted nuclei were centrifuged at 500 × g for
10 min, 4 °C. Pellets were re-suspended in transposase reaction mix
[25 μL 2× TD Buffer (Illumina Cat #FC-121-1030), 2.5 μL Tn5 Transposase (Illumina Cat #FC-121-1030) and 22.5 μL Nuclease Free H2O] on ice.
Samples were incubated at 37 °C for 30 min and then puriﬁed using the
MinElute Reaction Cleanup kit (Qiagen Cat #28204) according to
manufacturer’s instructions. Following puriﬁcation, library fragments
were ampliﬁed using the Nextera index kit (Illumina Cat #FC-121-1011),
under the following cycling conditions: 72 °C for 5 min, 98 °C for 30 s,
followed by thermocycling at 98 °C for 10 s, 63 °C for 30 s and 72 °C for
1 min for a total of ﬁve cycles. In order to prevent saturation due to
over-ampliﬁcation, a 5 µl aliquot was then removed and subjected to
qPCR for 20 cycles to calculate the optimal number of cycles needed
for the remaining 45 μL reaction. The additional number of cycles was
determined as follows: (1) Plot linear Rn vs. Cycle,(2) Calculate the # of
cycle that is corresponded to 1⁄4 of maximum ﬂuorescent intensity. In
general, we found adding 4–6 cycles to this estimate yielded optimal
ATAC-seq libraries. Libraries were ampliﬁed for a total of 13–19 cycles.
Following PCR, ATAC-seq libraries were puriﬁed and double-end sizeselected by (0.5× ratio and 1.8× ratio) Ampure XP bead puriﬁcation
(Beckman Coulter cat#; A63881) to remove primer-dimers (<100 bp)
and large fragments (>1000 bp). Library size was quantiﬁed using
Bioanalyzer High Sensitivity DNA Chips (Agilent technologies
Cat#5067-4626). Libraries were quantiﬁed by quantitative PCR (KAPA
Biosystems Cat#KK4873) prior to sequencing. Libraries were
sequenced on NovaSeq 6000 System (Illumina) obtaining 2 ×50
paired-end reads.
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CHIP-SEQ/ATAC-SEQ analyses
For SMARCA2/4 ChIP-seq and neuronal ATAC-seq from adult mouse
hippocampus, raw sequencing reads were aligned to the mouse genome (mm10) using default settings of HISAT262. Only uniquely mapped
reads were retained. Alignments were ﬁltered using SAMtools (v1.19)68
to remove duplicate reads. For ChIP-seq, peak-calling–normalized to
respective inputs–was performed using MACS (v2.1.124)69 with default
settings; the window size was set as 300 bp. For ATAC-seq, peak calling
was performed using MACS (v2.1.124) with settings --nomodel --shift
−100 --extsize 200. For both ChIP-seq and ATAC-seq datasets, peaks
were ﬁltered for FDR < 0.05 and fold change >1.2. Differential analyses
were performed using diffReps70 with a window size of 1 kb. A default
p-value cutoff of 0.0001 was used. Peaks and differential sites were
further annotated to nearby genes or intergenic regions using the
region analysis tool from the diffReps package (v1.55.6). Histone PTM
enrichment data in mouse hippocampus were extracted from published sources71. ATAC-seq differential lists were compared to ChIP-seq
differential lists based on gene names using geneOverlap (GeneOverlap: Test and visualize gene overlaps. R package version 1.23.0,
http://shenlab-sinai.github.io/shenlab-sinai/), and heat maps were
drawn using the deepTools package72.
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under accession numbers GSE210117 and GSE151255. We declare that
the data supporting ﬁndings for this study are available within the
article and Supplementary Information (see Supplemental Fig. 15 at the
end of the Supplementary Information ﬁle for all uncropped blots with
MW markers performed in this study). Source Data are provided with
this paper. No restrictions on data availability apply. Source data are
provided with this paper.
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